The #1 Energy Stock to Buy
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Get the Name & Ticker Here
Bahram Valamehr net worth and biography

Bahram Valamehr Biography and Net Worth

Insider of Fate Therapeutics
Bahram (Bob) Valamehr is the Chief Research and Development Officer at Fate Therapeutics, overseeing the company’s research and development activities. Previously, Dr. Valamehr has held the positions of Chief Development Officer and Vice President of Cancer Immunotherapy at Fate and prior to that played key scientific roles at Amgen, the Center for Cell Control (a NIH Nanomedicine Development Center) and the Broad Stem Cell Research Center developing novel methods to control pluripotency, to modulate stem cell fate including hematopoiesis and to better understand cellular signaling pathways associated with cancer. He has co-authored numerous studies and patents related to stem cell biology, oncology and materials science. Dr. Valamehr received his Ph.D. from the Department of Molecular and Medical Pharmacology at UCLA, his M.B.A. from Pepperdine University and his B.S. from the Department of Chemistry and Biochemistry at UCLA.

What is Bahram Valamehr's net worth?

The estimated net worth of Bahram Valamehr is at least $1.14 million as of January 10th, 2023. Dr. Valamehr owns 168,917 shares of Fate Therapeutics stock worth more than $1,143,568 as of February 6th. This net worth estimate does not reflect any other assets that Dr. Valamehr may own. Learn More about Bahram Valamehr's net worth.

How do I contact Bahram Valamehr?

The corporate mailing address for Dr. Valamehr and other Fate Therapeutics executives is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. Fate Therapeutics can also be reached via phone at (858) 875-1800 and via email at [email protected] Learn More on Bahram Valamehr's contact information.

Has Bahram Valamehr been buying or selling shares of Fate Therapeutics?

In the last ninety days, Bahram Valamehr has sold $57,205.08 of Fate Therapeutics stock. Most recently, Bahram Valamehr sold 10,917 shares of the business's stock in a transaction on Tuesday, January 10th. The shares were sold at an average price of $5.24, for a transaction totalling $57,205.08. Following the completion of the sale, the insider now directly owns 168,917 shares of the company's stock, valued at $885,125.08. Learn More on Bahram Valamehr's trading history.

Who are Fate Therapeutics' active insiders?

Fate Therapeutics' insider roster includes Yu-Waye Chu (VP), Edward Dulac, III (CFO), John Mendlein (Director), Louis Petrillo (Insider), Mark Plavsic (Insider), Cindy Tahl (General Counsel), Bahram Valamehr (Insider), and J. Wolchko (CEO). Learn More on Fate Therapeutics' active insiders.

Are insiders buying or selling shares of Fate Therapeutics?

In the last year, Fate Therapeutics insiders bought shares 2 times. They purchased a total of 124,679 shares worth more than $698,138.49. In the last year, insiders at the biopharmaceutical company sold shares 14 times. They sold a total of 224,549 shares worth more than $5,466,114.43. The most recent insider tranaction occured on January, 13th when Director John Mendlein bought 36,631 shares worth more than $198,906.33. Insiders at Fate Therapeutics own 17.3% of the company. Learn More about insider trades at Fate Therapeutics.

Information on this page was last updated on 1/13/2023.

Bahram Valamehr Insider Trading History at Fate Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/10/2023Sell10,917$5.24$57,205.08168,917View SEC Filing Icon  
7/7/2022Sell17,158$30.23$518,686.34179,834View SEC Filing Icon  
1/10/2022Sell5,596$46.38$259,542.48View SEC Filing Icon  
12/13/2021Sell25,000$47.66$1,191,500.00View SEC Filing Icon  
6/14/2021Sell25,000$89.32$2,233,000.00111,896View SEC Filing Icon  
3/15/2021Sell25,000$92.35$2,308,750.00120,740View SEC Filing Icon  
1/8/2021Sell6,230$117.10$729,533.0084,455View SEC Filing Icon  
1/8/2020Sell5,700$20.69$117,933.0091,758View SEC Filing Icon  
10/15/2019Sell6,200$14.18$87,916.00View SEC Filing Icon  
See Full Table

Bahram Valamehr Buying and Selling Activity at Fate Therapeutics

This chart shows Bahram Valamehr's buying and selling at Fate Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Fate Therapeutics Company Overview

Fate Therapeutics logo
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
Read More

Today's Range

Now: $6.77
Low: $6.60
High: $6.88

50 Day Range

MA: $10.68
Low: $4.24
High: $20.91

2 Week Range

Now: $6.77
Low: $4.02
High: $43.12


1,578,122 shs

Average Volume

5,438,172 shs

Market Capitalization

$657.84 million

P/E Ratio


Dividend Yield



A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
[Full Story]